XBRL 30 June 2023 filed with the SEC
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 15 August 2023. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$4.74 million cash refund from the Australian Taxation Office under the Australian Government’s Research and ...
Highlights: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 31 July 2023. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2023 (Q4 ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will present a corporate overview and participate in a Q&A discussion at the MST Access Rare Diseases, Rich Returns Forum on Thursday, ...
– Presentations Convey Novel Approach for Improving Diagnostic Accuracy and Tracking Disease Severity in MSA – – Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 31 August 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to ...
New Patent Covers Over 150 Novel Compounds MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 23 August 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the European Patent Office has granted Alterity a new composition of matter patent. The ...
– Presentations Highlight New Data on Diagnostic Accuracy and Novel Biomarkers of Disease Severity in Multiple System Atrophy – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 22 August 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that poster ...
– ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 – – Top-Line Data Expected by the End of 2024 – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) recommended the ...
– ATH434 now being evaluated in early and more advanced Multiple System Atrophy – – New trial expected to generate data before ongoing Phase 2 trial – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 May 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...
Receive news from Alterity Therapeutics
